Patient demographics, clinical baseline characteristics, clinical findings assessed prior to prasugrel treatment (or before initial PCI), during hospitalization, and at discharge, and the final diagnosis of ACS were assessed. The extent of exposure to prasugrel was based on the time and date of administration of the LD, the MD, the daily dose, the duration of treatment, and continuation or discontinuation of treatment. Other variables assessed were use of other anti-platelet agents/anti-coagulants and other concomitant medications, invasive procedures other than PCI/coronary artery bypass graft, initial coronary angiography (CAG) findings if the patient underwent CAG, timing of prasugrel administration (before, during, or after PCI), vital signs, laboratory data, AEs, bleeding AEs, and cardiovascular events.